VSTM / Verastem: Updated Avutometinib Data Brings My Position Out Of Mothballs

Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is b more_horizontal

Verastem Oncology presented promising data from their RAMP 201 program of Avutometinib monotherapy or in combination with Defactinib for the treatment more_horizontal

The tech sector, a perpetually booming industry, presents an ocean of opportunities for investors, particularly those interested in trading penny stoc more_horizontal

Everyone is looking for an edge to find penny stocks to buy before the masses. The difficult part of this is that many of these cheap stocks lack liqu more_horizontal

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, more_horizontal

With the third month of 2023 already well underway, the ripple effect from the collapse of multiple banks in the United States is felt far and wide, l more_horizontal

Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might driv more_horizontal

Verastem's RAF/MEK/FAK inhibitor program is progressing nicely. They are releasing decent data with no sudden surprises. more_horizontal